Early but not serial ustekinumab concentration measurements are associated with clinical outcomes in Crohn's disease and ulcerative colitis: the Stockholm Ustekinumab study (STOCUSTE).
INTRODUCTION Ustekinumab (UST), an anti-interleukin-12/23 antibody, is used to treat moderate-to-severe inflammatory bowel disease (IBD). The STOCUSTE study includes IBD patients treated with UST at four teaching hospitals in Stockholm to provide long-term follow-up data. The utility of therapeutic drug monitoring to o...